Khaleej Times

Epilepsy drug behind 4,100 birth defects

-

paris — The epilepsy medication valproate is responsibl­e for “severe malformati­ons” in 2,150 to 4,100 children in France since the drug was first marketed in the country in 1967, according to a preliminar­y study by French health authoritie­s.

Women who took the drug during pregnancy to treat epilepsy were four times more likely to give birth to babies with congenital malformati­ons, said the report, jointly issued by the French National Agency for the Safety of Medicines (ANSM) and the national health insurance administra­tion.

“The study confirms the highly teratogeni­c” — that is, capable of causing birth defects — “nature of valproate,” said Mahmoud Zureik, scientific director of ANSM and a co-author of the report.

“The figure of about 3,000 severe malformati­ons is very high,” he said. The types of birth defects attributed to the drug included spina bifida — a condition in which the spinal cord does not form properly, and can protrude through the skin — as well as defects of the heart and genital organs.

The risk of autism and developmen­tal problems was also found to be higher, and will be quantified in a follow-up report later this year.

An earlier estimate suggested that 30 to 40 per cent of children exposed in the womb could suffer such disorders.

From 1967 to 2016, between 64,100 and 100,000 pregnancie­s in France were exposed to valproate, resulting in 41,200 to 75,300 live births, according to the report.

The vast majority of the birth defects occurred for women under treatment for epilepsy.

But starting in the late 1970s, valproate — marketed around the world as Depakine, Depakote, Stavzor and other trade names — was also prescribed in France to treat bi-polar disorder.

Bi-polar women taking the drug were twice as likely to give birth to children with major birth defects, the study found.

The lower risk compared with women treated for epilepsy probably stems from the fact that — for pregnant bi-polar women — doctors stopped prescribin­g valproate early in the pregnancy, Zureik said. — AFP

Newspapers in English

Newspapers from United Arab Emirates